Symphony Robotics, a pioneer in advanced neurosurgical micro-robotics, announced the appointment of renowned neurosurgeon Dr. Neil A. Martin as its Chief Medical Officer (CMO). In this pivotal role, Dr. Martin will lead the advancement of the company’s groundbreaking, engine-free, nonlinear, flexible micro-robotic system, poised to transform the treatment landscape for Glioblastoma Multiforme (GBM).
“Glioblastoma remains the most treatment-resistant and lethal primary brain tumor, with a median survival of only 14-16 months following maximal safe resection plus adjuvant chemoradiotherapy, and a five-year survival rate below 7%,” stated Dr. Martin. “Despite significant advances in molecular characterization and targeted therapeutics, meaningful improvements in clinical outcomes have remained elusive.”
Health Technology Insights: Lumicera Partners with Costco Pharmacy to Offer Cost-Plus Specialty Pharmacy and Enhanced Patient Support
Early preclinical studies using anatomically accurate GBM models under real-time MRI guidance have shown that Symphony Robotics’ platform achieves significant improvements in maneuverability, resulting in up to 3 times the volumetric coverage when compared with existing technologies, with millimeter-level precision, crucial for protecting critical healthy brain tissue while maximizing tumor removal.
Dr. Martin continued, “Symphony Robotics is positioned to transform the treatment paradigm by substantially extending the capabilities of Laser Interstitial Thermal Therapy (LITT) in GBM—potentially tripling the ablation volume achievable through its steerability after single-site minimally invasive insertion. Our initial objective is to significantly enhance the efficacy of LITT through precise, nonlinear navigation to previously unreachable tumor margins, even in large and irregular tumors. We are implementing an aggressive translational research pipeline for developing applications to accompany and synergize with thermal ablation, including targeted drug and immunotherapy delivery systems for precision neuro-oncology.”
Health Technology Insights: CytoAgents Completes Cohort 1 Dose-Escalation in Clinical Phase 1B for Cytokine Release Syndrome Research
“Symphony Robotics is built on a foundation of rigorous research and a robust intellectual property portfolio, supported by grants from the National Institutes of Health (NIH) and the National Science Foundation (NSF), and exclusively licensed from Case Western Reserve University,” said Mordechai (Moty) Avisar, Founder and CEO of Symphony Robotics. “Welcoming Dr. Martin—a visionary leader in neurosurgery—to our team marks a pivotal milestone that will accelerate our mission to revolutionize GBM treatment. By harnessing the power of artificial intelligence, our platform is poised to optimize therapy and deliver this life-changing technology to patients worldwide.”
The company is currently establishing collaborations with leading neurosurgical centers to initiate beta site testing later this year, ensuring thorough clinical assessment in diverse patient populations and anatomical scenarios.
Health Technology Insights: TOCCorp Launches HITMark to Accelerate Capital Project ROI for Healthcare Providers
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
